(LEGN) Legend Biotech - Overview
Stock: CAR-T Therapy, Multiple Myeloma, Oncology, Clinical Trials
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 64.5% |
| Relative Tail Risk | -5.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.41 |
| Alpha | -61.05 |
| Character TTM | |
|---|---|
| Beta | 0.443 |
| Beta Downside | 0.278 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.12% |
| CAGR/Max DD | -0.40 |
Description: LEGN Legend Biotech January 08, 2026
Legend Biotech Corp (NASDAQ: LEGN) is a U.S.–based biopharma that discovers, develops, manufactures, and commercializes novel cell-therapy products across the United States, China, and Europe. Founded in 2014 and headquartered in Somerset, New Jersey, the firm focuses on autologous and allogeneic CAR-T and CAR-NK platforms.
The company’s lead asset, ciltacabtagene autoleucel (cilta-cel), is a BC MA-directed CAR-T therapy for relapsed/refractory multiple myeloma that received FDA approval (as Carvykti) in early 2022 and has generated roughly $120 million in U.S. sales through Q3 2024, with a projected 2025 run-rate of $300 million based on current uptake trends.
Legend’s pipeline extends to earlier-stage autologous CAR-T candidates for a broad oncology spectrum-including NHL, ALL, gastric, esophageal, pancreatic, colorectal, hepatocellular, small-cell and non-small-cell lung cancers-as well as allogeneic γδ-CAR-T and CAR-NK programs targeting BC MA, currently in investigator-initiated Phase 1 trials in China.
Strategic collaborations underpin the business: a development and commercialization partnership with Janssen Biotech covers cilta-cel (revenue-share model with up-to $500 million in potential milestones), and a licensing deal with Novartis grants rights to delta-like ligand 3-targeted CAR-T therapies, expanding the company’s addressable market beyond hematology.
Industry-level drivers include a rapidly expanding CAR-T market-estimated to grow at a CAGR of ~30 % from 2023 to 2030-and favorable reimbursement trends in the U.S. and China, which together represent > $6 billion in annual multiple-myeloma therapy spend.
For a deeper dive into Legend Biotech’s valuation metrics and risk profile, see the ValueRay analyst page.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -239.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA -0.87 > 1.0 |
| NWC/Revenue: 88.94% < 20% (prev 207.5%; Δ -118.5% < -1%) |
| CFO/TA -0.10 > 3% & CFO -170.1m > Net Income -239.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (92.3m) vs 12m ago 1.05% < -2% |
| Gross Margin: 60.55% > 18% (prev 0.63%; Δ 5992 % > 0.5%) |
| Asset Turnover: 52.71% > 50% (prev 29.97%; Δ 22.74% > 0%) |
| Interest Coverage Ratio: -9.81 > 6 (EBITDA TTM -183.3m / Interest Expense TTM 21.1m) |
Altman Z'' -3.96
| A: 0.47 (Total Current Assets 1.24b - Total Current Liabilities 433.6m) / Total Assets 1.71b |
| B: -1.13 (Retained Earnings -1.93b / Total Assets 1.71b) |
| C: -0.12 (EBIT TTM -207.1m / Avg Total Assets 1.72b) |
| D: -2.46 (Book Value of Equity -1.73b / Total Liabilities 701.7m) |
| Altman-Z'' Score: -3.96 = D |
Beneish M -3.19
| DSRI: 0.01 (Receivables 1.30m/104.0m, Revenue 909.0m/520.2m) |
| GMI: 1.04 (GM 60.55% / 62.88%) |
| AQI: 1.21 (AQ_t 0.13 / AQ_t-1 0.10) |
| SGI: 1.75 (Revenue 909.0m / 520.2m) |
| TATA: -0.04 (NI -239.7m - CFO -170.1m) / TA 1.71b) |
| Beneish M-Score: -3.19 (Cap -4..+1) = AA |
What is the price of LEGN shares?
Over the past week, the price has changed by -7.94%, over one month by -18.72%, over three months by -45.74% and over the past year by -52.98%.
Is LEGN a buy, sell or hold?
- StrongBuy: 11
- Buy: 10
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LEGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 66.3 | 279% |
| Analysts Target Price | 66.3 | 279% |
| ValueRay Target Price | 15.8 | -9.9% |
LEGN Fundamental Data Overview January 28, 2026
P/S = 3.8521
P/B = 3.4719
Revenue TTM = 909.0m USD
EBIT TTM = -207.1m USD
EBITDA TTM = -183.3m USD
Long Term Debt = 171.9m USD (from longTermDebt, last quarter)
Short Term Debt = 150.2m USD (from shortTermDebt, last quarter)
Debt = 410.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 131.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.92b USD (3.50b + Debt 410.2m - CCE 992.6m)
Interest Coverage Ratio = -9.81 (Ebit TTM -207.1m / Interest Expense TTM 21.1m)
EV/FCF = -15.47x (Enterprise Value 2.92b / FCF TTM -188.7m)
FCF Yield = -6.46% (FCF TTM -188.7m / Enterprise Value 2.92b)
FCF Margin = -20.76% (FCF TTM -188.7m / Revenue TTM 909.0m)
Net Margin = -26.37% (Net Income TTM -239.7m / Revenue TTM 909.0m)
Gross Margin = 60.55% ((Revenue TTM 909.0m - Cost of Revenue TTM 358.6m) / Revenue TTM)
Gross Margin QoQ = 57.66% (prev 61.58%)
Tobins Q-Ratio = 1.70 (Enterprise Value 2.92b / Total Assets 1.71b)
Interest Expense / Debt = 1.38% (Interest Expense 5.64m / Debt 410.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -163.6m (EBIT -207.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.86 (Total Current Assets 1.24b / Total Current Liabilities 433.6m)
Debt / Equity = 0.41 (Debt 410.2m / totalStockholderEquity, last quarter 1.01b)
Debt / EBITDA = -0.72 (negative EBITDA) (Net Debt 131.3m / EBITDA -183.3m)
Debt / FCF = -0.70 (negative FCF - burning cash) (Net Debt 131.3m / FCF TTM -188.7m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -13.90% (Net Income -239.7m / Total Assets 1.71b)
RoE = -23.36% (Net Income TTM -239.7m / Total Stockholder Equity 1.03b)
RoCE = -17.28% (EBIT -207.1m / Capital Employed (Equity 1.03b + L.T.Debt 171.9m))
RoIC = -12.26% (negative operating profit) (NOPAT -163.6m / Invested Capital 1.33b)
WACC = 6.87% (E(3.50b)/V(3.91b) * Re(7.55%) + D(410.2m)/V(3.91b) * Rd(1.38%) * (1-Tc(0.21)))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.75%
Fair Price DCF = unknown (Cash Flow -188.7m)
EPS Correlation: 29.25 | EPS CAGR: 6.89% | SUE: 0.16 | # QB: 0
Revenue Correlation: 87.61 | Revenue CAGR: 67.92% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.09 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.25 | Chg30d=+0.192 | Revisions Net=-1 | Growth EPS=+115.9% | Growth Revenue=+45.0%